Skip to main content
SpringerLink
Log in
Book cover

Menopause pp 91–107Cite as

Genitourinary Syndrome of the Menopause: Vaginal Health and Microbiota

  • Chapter
  • First Online:

Abstract

The genitourinary syndrome of menopause (GSM) is a new term that describes various menopausal symptoms and signs including not only genital and sexual symptoms but also urinary symptoms related to a decreased estrogen level in menopause.

Since the GSM may have a negative impact on the quality of life of postmenopausal women, women should be made aware of these problems and treated with an appropriate effective therapy. Thus, in this review we introduce new terminology and discuss the importance and the role played by the vaginal microbiota in the vaginal health.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Cornellana MJ. Atrofia vaginal, una enfermedad crónica con repercusión en la calidad de vida. Revista iberoamericana de revisiones en menopausia. 2007;9(2):2.

    Google Scholar 

  2. Portman DJ, Gass ML. Vulvovaginal atrophy terminology consensus conference panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Maturitas. 2014;79(3):349–54. doi:10.1016/j.maturitas.2014.07.013.

    Article  CAS  PubMed  Google Scholar 

  3. Menoguia Salud vaginal. Asociación Española para el Estudio de la Menopausia. 2014. ISBN: 978-84-940319-5-3.

    Google Scholar 

  4. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62:45–51.

    Article  PubMed  Google Scholar 

  5. Cancelo MJ, Beltrán D, Calaf J, Campillo F, Cano A, Guerra JA, Neyro JL. Protocolo Sociedad Española de Ginecología y Obstetricia de diagnóstico y tratamiento de las infecciones vulvovaginales. Prog Obst Gynecol. 2013;56(5):278–84.

    Article  Google Scholar 

  6. Döderlein ASG. Das Scheidensekret und seine bedeutung für das puerperalfieber. Leipzig: O. Durr; 1892.

    Google Scholar 

  7. Miller EA, Beasley DE, Dunn RR, Archie EA. Lactobacilli dominance and vaginal pH: why is the human vaginal microbiome unique? Front Microbiol. 2016;7:1936. doi:10.3389/fmicb.2016.01936.

    PubMed  PubMed Central  Google Scholar 

  8. Álvarez-Olmos MI, Barousse MM, Rajan L, Van Der Pol BJ, Fortenberry D, Orr D, et al. Vaginal lactobacilli in adolescents: presence and relationship to local and systemic immunity, and to bacterial vaginosis. Sex Trans Dis. 2004;31:393–400.

    Article  Google Scholar 

  9. Zhou X, Bent S, Schneider M, Davis C, Islam M, Forney L. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. Microbiology. 2004;150:2565–73.

    Article  CAS  PubMed  Google Scholar 

  10. Li J, McCormick J, Bocking A, Rei G. Importance of vaginal microbes in reproductive health. Reprod Sci. 2012;19(3):235–42.

    Article  CAS  PubMed  Google Scholar 

  11. Gajer P, Brotman RM, Bai G, Sakamoto J, Schütte UM, Zhong X, Koenig SS, Fu L. Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2012;4(132):132RA52.

    Article  PubMed  PubMed Central  Google Scholar 

  12. MacPhee RA, Hummelen R, Bisanz JE, Miller WL, Reid G. Probiotic strategies for the treatment and prevention of bacterial vaginosis. Expert Opin Pharmacother. 2010;11(18):2985–95.

    Article  PubMed  Google Scholar 

  13. Boyd MA, Antonio MA, Hillier SL. Comparison of API 50 CH strips to whole-chromosomal DNA probes for identification of Lactobacillus species. J Clin Microbiol. 2005;43:5309–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hyman R, Fukushima M, Diamond L, Kumm J, Giudice L, Davis R. Microbes on the human vaginal epithelium. Proc Natl Acad Sci U S A. 2005;102:7952–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Reid G, Burton J, Devillard E. The rationale for probiotics in female urogenital healthcare. Med Gen Med. 2004;29:6–49.

    Google Scholar 

  16. Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science. 2012;336(6086):1255–62. doi:10.1126/science.1224203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kenyon CR, Osbak K. Recent progress in understanding the epidemiology of bacterial vaginosis. Curr Opin Obstet Gynecol. 2014;26(6):448–54.

    Article  PubMed  Google Scholar 

  18. Stamey TA. The role of introital enterobacteria in recurrent urinary infections. J Urol. 1973;109:467–72.

    Article  CAS  PubMed  Google Scholar 

  19. Cancelo Hidalgo MJ, de la Fuente P. Perception ans attitude of spanish gynaecologists towards women with integral perineal symptomatology (IPS). In: 8th European Congress on MenoReid G, Bruce AW. Urogenital infections in women: can probiotics help? World J Urol. 2003;24:28–32. pause (EMAS) London, 16–20 May 2009.

    Google Scholar 

  20. Hodgins MB, Spike RC, Mackie RM, MacLean AB. An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br J Obstet Gynaecol. 1998;105:216–22.

    Article  CAS  PubMed  Google Scholar 

  21. Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int. 2000;86:32–8.

    Article  CAS  PubMed  Google Scholar 

  22. Arnold JJ, Hehn LE, Klein DA. Common questions about recurrent urinary tract infections in women. Am Fam Physician. 2016;93(7):560–9.

    PubMed  Google Scholar 

  23. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:888–902.

    Article  Google Scholar 

  24. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17:3–9.

    Article  CAS  PubMed  Google Scholar 

  25. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67:233–8.

    Article  PubMed  Google Scholar 

  26. Freedman MA. Quality of life and menopause: the role of estrogen. J Womens Health (Larchmt). 2002;11:703–18.

    Article  Google Scholar 

  27. Palacios S, Cancelo MJ, Castelo Branco C, Llaneza P, Molero F, Sanchez Borrego R. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perception. Climacteric. 2017;20(1):55–61. doi:10.1080/13697137.2016.1262840.

    Article  CAS  PubMed  Google Scholar 

  28. Raz R. Urinary tract infection in postmenopausal women. Korean J Urol. 2011;52:801–8.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Goldstein I, Dicks B, Kim NN, Hartzell R. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med. 2013;1(2):44–53. doi:10.1002/sm2.17.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Palacios S, Cancelo MJ. Guía práctica de asistencia del síndrome urogenital de la menopausia (SEGO). Actualización 2015. Madrid: SEGO, España.

    Google Scholar 

  31. Johnston SL, Farrell SA, Bouchard C, Farrell SA, Beckerson LA, Comeau M, Johnston SL, Lefebvre G, Papaioannou A, SOGC Joint Committee-Clinical Practice Gynaecology and Urogynaecology. The detection and management of vaginal atrophy. J Obstet Gynaecol Can. 2004;26(5):503–15.

    Article  PubMed  Google Scholar 

  32. O’Connell TX, Nathan LS, Satmary WA, Goldstein AT. Non-neoplastic epithelial disorders of the vulva. Am Fam Physician. 2008;77(3):321–6.

    PubMed  Google Scholar 

  33. Bachmann GA, Notelovitz M, Kelly SJ, et al. Long-term nonhormonal treatment of vaginal dryness. Clin Pract Sex. 1992;8:12.

    Google Scholar 

  34. Palacios S, Mejias A. An update on drugs for the treatment of menopausal symptoms. Expert Opin Pharmacother. 2015;16(16):2437–47. doi:10.1517/14656566.2015.1085508.

    Article  CAS  PubMed  Google Scholar 

  35. Origoni M, Cimmino C, Carminati G, Iachini E, Stefani C, Girardelli S, Salvatore S, Candiani M. Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective, observational study. Eur Rev Med Pharmacol Sci. 2016;20(20):4190–5.

    CAS  PubMed  Google Scholar 

  36. Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Candiani M, Leone Roberti Maggiore U. A 12-week treatment with fractional CO2 laser for vulvo-vaginal atrophy: a pilot study. Climacteric. 2014;17:363–9.

    Article  CAS  PubMed  Google Scholar 

  37. Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas. 2016;91:42–50. doi:10.1016/j.maturitas.2016.05.015.

    Article  PubMed  Google Scholar 

  38. Leiblum S, Bachmann G, Kemmann E, et al. Vaginal atrophy in the postmenopausal woman: the importance of sexual activity and hormones. JAMA. 1983;249:2195.

    Article  CAS  PubMed  Google Scholar 

  39. Palacios S, Coronado PJ. Treatment of menopausal symptoms. New era with new options or new options for menopausal symptoms after 15 years of WHI study. Minerva Ginecol. 2016;14.

    Google Scholar 

  40. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;8:CD001500. doi:10.1002/14651858.CD001500.pub3.

    Google Scholar 

  41. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92:722.

    CAS  PubMed  Google Scholar 

  42. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;4:CD001500.

    Google Scholar 

  43. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  44. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121–34. doi:10.3109/13697137.2014.947254.

    Article  CAS  PubMed  Google Scholar 

  45. Simon JA, Maamari RV. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy. Climacteric. 2013;16(Suppl 1):37–43. doi:10.3109/13697137.2013.807606.

    Article  CAS  PubMed  Google Scholar 

  46. Del Pup L, Di Francia R, Cavaliere C, Facchini G, Giorda G, De Paoli P, Berretta M. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients? Anticancer Drugs. 2013;24(10):989–98. doi:10.1097/CAD.0b013e328365288e.

    Article  CAS  PubMed  Google Scholar 

  47. Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas. 2005;50(2):98–104.

    Article  CAS  PubMed  Google Scholar 

  48. Farrell R, American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, ACOG Committee Opinion No. 659. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;27(3):e93–6. doi:10.1097/AOG.0000000000001351.

    Google Scholar 

  49. Mendoza N, Abad P, Baró F, Cancelo MJ, Llaneza P, Manubens M, Quereda F, Sánchez-Borrego R. Spanish Menopause Society position statement: use of tibolone in postmenopausal women. Menopause. 2013;20(7):754–60. doi:10.1097/GME.0b013e31827b18c5.

    Article  PubMed  Google Scholar 

  50. D'Anna R, Cannata ML, Atteritano M, Cancellieri F, Corrado F, Baviera G, Triolo O, Antico F, Gaudio A, Frisina N, Bitto A, Polito F, Minutoli L, Altavilla D, Marini H, Squadrito F. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. Menopause. 2007;14(4):648–55.

    Article  PubMed  Google Scholar 

  51. Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014;11(2):487–97.

    Article  CAS  PubMed  Google Scholar 

  52. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001;77(4–5):271–9.

    Article  CAS  PubMed  Google Scholar 

  53. Palacios S, Cancelo MJ. Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. Int J Women Health. 2016;8:617–26.

    Article  Google Scholar 

  54. DeGregorio MW, Zerbe RL, Wurz GT. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids. 2014;90:82–93.

    Article  CAS  PubMed  Google Scholar 

  55. Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226–32.

    Article  CAS  PubMed  Google Scholar 

  56. European Medicines Agency. Senshio Summary of Product Characteristics. EMA. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002780/WC500182775.pdf (2015). Accessed 1 Dec 2016.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Obstetrics and Gynecology Department, Universitary Hospital of Guadalajara (Spain), University of Alcalá, Madrid, Spain

    Maria Jesús Cancelo-Hidalgo & Laura Barrera Coello

Authors
  1. Maria Jesús Cancelo-Hidalgo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Barrera Coello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Jesús Cancelo-Hidalgo .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain

    Antonio Cano

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Cancelo-Hidalgo, M.J., Coello, L.B. (2017). Genitourinary Syndrome of the Menopause: Vaginal Health and Microbiota. In: Cano, A. (eds) Menopause. Springer, Cham. https://doi.org/10.1007/978-3-319-59318-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59318-0_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59317-3

  • Online ISBN: 978-3-319-59318-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation